Cargando…
Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation
It has been suggested that some cancer cells rely upon fatty acid oxidation (FAO) for energy. Here we show that when FAO was reduced approximately 90% by pharmacological inhibition of carnitine palmitoyltransferase I (CPT1) with low concentrations of etomoxir, the proliferation rate of various cance...
Autores principales: | Yao, Cong-Hui, Liu, Gao-Yuan, Wang, Rencheng, Moon, Sung Ho, Gross, Richard W., Patti, Gary J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892939/ https://www.ncbi.nlm.nih.gov/pubmed/29596410 http://dx.doi.org/10.1371/journal.pbio.2003782 |
Ejemplares similares
-
Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres
por: Shim, Jin-Kyoung, et al.
Publicado: (2022) -
A surviving 24-month-old patient with neonatal-onset carnitine palmitoyltransferase II deficiency
por: Ikeda, Naohiro, et al.
Publicado: (2017) -
Carnitine palmitoyltransferase 2 deficiency, malignant hyperthermia and anesthesia
por: Glauber, Violeta, et al.
Publicado: (2014) -
Severe rhabdomyolysis in homozygote carnitine palmitoyltransferase II deficiency
por: Schnedl, Wolfgang J., et al.
Publicado: (2020) -
Stabilization of the thermolabile variant S113L of carnitine palmitoyltransferase II
por: Motlagh, Leila, et al.
Publicado: (2016)